JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View

Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $5.30 per share in second-quarter 2024, beating the Zacks Consensus Estimate of $4.68. Earnings rose 18% year over year. Total revenues in the reported quarter rose 7% year over year to $1.02 billion. Sales of Xywav, Epidiolex and Rylaze drove the upside. The reported figure beat the Zacks Consensus Estimate of $1.0 billion. Quarter in Detail Net product sales rose 2% year over year at $964.1 million. The reported figure beat the Zacks Consensus Esti ...